Type a question in ordinary words. Answers are grounded in retrieved KPSGILL pages and identified sources; questions the library cannot support are declined rather than answered from model memory. No advice is given, and no personal health information is accepted.
531 current articles: 398 policy analyses, 127 patient guides, 3 standing trackers and 3 cross-cutting essays, plus 107 superseded records kept at their original addresses. Ask in your own words.
This week’s records, read at the bodies that issued them. Each carries its instrument, its state and its source — a proposal is not law, an agenda is not a decision, a closed comment period is not a final rule, and an audit finding is not a finding of fraud. Updated 19 August 2026.
Early AlertUnited States · FDA · CDRH · Neonatal
Neonatal CPAP sets with loose cannula connections: do not use affected lots, FDA’s alert says
Specific lots of CooperSurgical’s INCA neonatal nasal CPAP complete and replacement sets may lose the connection between tubing and cannula — loss of CPAP pressure and decreased oxygenation until restored. The instruction is removal: cease use and return; swap tubing or device if it loosens mid-use. No serious injuries or deaths reported as of the 11 August customer letter; not a final recall classification.
The Board adjourns — and the official outcome record is now the wait
The August meeting — panels on the 19th, the quarterly Board 20–21 August — has concluded. On the record read 24 August, no action summary or approved minutes had been located: every agenda item, from the eighteen legislative positions to each panel’s disciplinary matters, holds one state — disposition not yet identified in the publicly available record. Outcomes populate from the official record, never the room.
Public meeting concluded · outcomes pending · Record · Tracker
Effective 21 AugCalifornia · DHCS · Medi-Cal Rx
The Medi-Cal Rx early-refill change is now the rule at the counter
Effective 21 August, refill-too-soon processing for members 21 and older runs under the revised thresholds. A refused refill this week is the new rule working as written, not a coverage loss: no drug left the benefit and no member lost eligibility.
Benefit policy change · final · effective · Record · Ledger
Early AlertsUnited States · FDA · CDRH
Three device Early Alerts: recalled saline in epidural kits, software that drops monitored patients, neonatal circuits pulled
Epidural and convenience kits may contain recalled Huons saline — with spine-proximity risks stated up to meningitis and paralysis; GE HealthCare’s Portrait monitoring software can remove patients and reset alarms during updates; Medline’s neonatal heated-wire breathing circuits are being removed for connector thermal damage. Each alert reports no serious injuries or deaths as of its source date — and none is a final recall classification.
Free rescue inhalers for 10,000 schools, on one statewide standing order
Two albuterol inhalers and 25 spacers per year, free for three years, to every public and charter TK–12 school — shipped under CDPH’s standing order rather than individual prescriptions, with training through the school-nurse workforce. Announced 20 August; private schools buy at $9.50 an inhaler.
Two years for a $110 million telemedicine scheme built on signatures without examinations
The former owner of two telemedicine companies was sentenced in Boston for a Medicare DME scheme: prepopulated orders signed by recruited clinicians, typically without any patient contact, then sold on to suppliers. Adjudicated by guilty plea — and a case study in what converts telehealth staffing offers into billable fraud.
A first therapy for glycogen storage disease type Ia — with the confirmation still owed
FDA granted accelerated approval to Genglycos, a one-time gene therapy and the first approved treatment for GSDIa, indicated to reduce daily cornstarch intake in patients 8 and older. The endpoint is the burden of management, not a hard outcome — and confirmatory trials remain required.
A second treatment for fibrodysplasia ossificans progressiva — and the first addressing flare-ups
FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification and clinician-assessed flare-ups in adults with FOP — the ultra-rare disorder in which connective tissue turns to bone. Trial: 2 and 1 new lesions on the two doses versus 19 on placebo over 56 weeks. Fetal-harm warning; contraception through 6 months after the last dose. Per FDA, the second drug approved for the disease.
FDA opens a public docket on regulating generative-AI medical devices
A discussion paper issued asks how generative-AI devices should be assessed for risk, evaluated before market and monitored after it — including a premarket model built on competency assessment. It is not a rule and not guidance: FDA states it proposes no policy. Feedback to docket FDA-2026-N-7874 closes 19 October.
Discussion paper · FDA Center for Devices and Radiological Health
Closes 30 AugustEuropean Union · EMA
Europe reopens a guideline because quitting-smoking medicines were never studied in vaping
EMA’s concept paper records that its smoking-cessation guideline is neither intended for nor fully applicable to dependence on nicotine delivered without combustion — and is being applied to it anyway. The proposal extends it to all forms of nicotine dependence. A concept paper is not a guideline.
Medicare drug-price negotiation: the comment period closed on 17 August
The comment period on the proposed rule for the Medicare Drug Price Negotiation Program and the Part D benefit closed . Two state axes move separately: the window is closed and the rule is still a proposal. Nothing became final on that date.
Proposed rule · Centers for Medicare & Medicaid Services
Executive orderUnited States · The White House
An order states childhood vaccine recommendations — and directs a plan to split the MMR
Executive Order 14420 recognises recommendations covering 11 diseases on the White House’s own comparison, moves the rest to shared clinical decision-making, and directs HHS to plan for single-disease core vaccines starting with MMR — once such products are domestically available. It amends no schedule, licenses no product, creates no enforceable right and changes no school-entry rule.
EO 14420 · 91 FR 53173 · plans due 8 November · Record
ConsultationAustralia · TGA
TGA consults on making more of the device record public
A consultation running 13 August to 2 October 2026 on expanding what the TGA may lawfully release about medical devices under section 61 of the Therapeutic Goods Act 1989. A consultation is not a decision.
Consultation · Therapeutic Goods Administration
Effective 1 Jan 2027California · DHCS
A whole population leaves managed care — and the deadline lands on the practice
Medi-Cal members with unsatisfactory immigration status move to fee-for-service on 1 January 2027. Eligibility does not change; payment does. A provider not approved through PAVE by that date is unpaid for a patient who is still covered, members are no longer assigned a primary care provider, and Enhanced Care Management and Community Supports do not exist in fee-for-service.
Delivery-system change · enrollment deadline attached · Record
Proposed pathwayUnited States · CMS & FDA
Medicare proposes same-day coverage review for breakthrough devices
The RAPID pathway would issue a proposed national coverage determination the same day FDA authorises an eligible Breakthrough Device, with final coverage targeted 60–90 days after authorisation instead of the year or more the gap has run. Coverage evidence expectations would be negotiated during trial design — which is where the real change sits. Comments close 13 October.
Procedural notice CMS-3487-NC · proposed, not operative · Federal Register
Accelerated approvalUnited States · FDA
FDA grants accelerated approval to Tudriqev in refractory advanced melanoma
On 6 August 2026 the FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an HSV-1 oncolytic viral therapy, with nivolumab, for anti-PD-1 refractory disease. Accelerated approval rests on a surrogate endpoint and carries a confirmatory-trial obligation.
Marketing authorisation · Food and Drug Administration
Audit findingUnited States · HHS OIG
OIG projects $15.2 million in improper payments for sacroiliac-joint injections
OIG reviewed sessions billed to Medicare between 1 October 2023 and 30 September 2024. Of a 100-session sample, 72 did not comply with Medicare requirements. An audit finding is not a fraud finding and not a rule change.
Audit report · HHS Office of Inspector General
Pathway17The physician-investigation process, stage by stage.Interactive walkthrough — in the workspace
Every page names its reviewing physician and its review date. Where claim-level authority has been mapped, the evidence can be inspected directly, down to the instrument each proposition rests on. Nothing is deleted. Superseded analyses remain at their own addresses, marked as superseded and pointing to the current record, with its original text retained. Editorial standards & ledger